GGrantIndex
Sort

23,748 grants matching melanoma

Controlled Release of Macromolecules

$399,667
Robert S Langer · Massachusetts Institute Of Technology · R37 · FY2012 · EB

Large-Scale Characterization of Anti-Cancer Antibody Responses in Lung Adenocarci

$399,643
William H Robinson · Stanford University · R33 · FY2014 · CA

Large-Scale Characterization of Anti-Cancer Antibody Responses in Lung Adenocarci

$399,643
William H Robinson · Stanford University · R33 · FY2016 · CA

Large-Scale Characterization of Anti-Cancer Antibody Responses in Lung Adenocarci

$399,643
William H Robinson · Stanford University · R33 · FY2015 · CA

Integrative Cancer Genomics: Drivers, Pathways and Drugs

$399,632
Dana Pe'er · Columbia Univ New York Morningside · R01 · FY2012 · CA

PLA2G2D Antibodies for Cancer Immunotherapy

$399,618
Li-Fen Lee · Apeximmune Therapeutics Inc. · R43 · FY2023 · CA

Project 2

$399,609
Ryan Bruce Corcoran · Massachusetts General Hospital · U54 · FY2020 · CA

TARGETING EPIGENETIC REGULATOR JARIDIB IN MALIGNANT MELANOMA

$399,600
Yale Univ · · FY2013 · Department of Defense

Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer

$399,586
Fatemeh Sadat Majedi · Symphony Biosciences, Inc. · R44 · FY2023 · CA

ERK control of Dendritic Cell Differentiation, Homeostasis and Disease

$399,583
Miriam Merad · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · CA

Platelet Serine/Threonine Phosphatases in Cancer Pathophysiology

$399,554
K. Vinod Vijayan · Baylor College Of Medicine · R01 · FY2024 · CA

Development of Programmable mRNA Circuits for Melanoma Immunotherapy

$399,508
Ryan Sowell · Strand Therapeutics Inc · R43 · FY2021 · CA

An innovative telomerase-targeted, circulating tumor cell assay for monitoring NSCLC treated with radiation and immunotherapy

$399,499
Deeksha Saxena · Liquid Biodx Llc · R43 · FY2023 · CA

SOUTHWEST ONCOLOGY GROUP

$399,443
Swedish Medical Center, First Hill · U10 · FY2002 · CA

The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy

$399,379
Benjamin Izar · Columbia University Health Sciences · R01 · FY2023 · CA

Targeting of Mitochondrial Lon Protease as a Novel Therapy for Glioblastoma

$399,338
Daniela Annenelie Bota · University Of California-Irvine · R01 · FY2024 · NS

Understanding PPARgamma signaling in melanoma brain metastasis

$399,305
Qing Chen · Wistar Institute · R01 · FY2023 · CA

Targeted Delivery of Tumor Antigen esaRNA to the Spleen for Cancer Immunotherapy

$399,300
Jasdave Chahal · Tiba Biotech, Llc · R43 · FY2025 · CA

Augmenting focused ultrasound-mediated drug delivery to brain tumors with vascular normalization

$399,294
Richard J Price · University Of Virginia · R21 · FY2024 · CA

Activation and Regulation of the Understudied Kinome Using MIB/MS Technology

$399,282
Gary L. Johnson · Univ Of North Carolina Chapel Hill · U01 · FY2014 · MH

Role of Desmoglein 1 in Keratinocyte-Melanocyte Communication and Melanoma

$399,195
Kathleen Janee Green · Northwestern University At Chicago · R01 · FY2021 · CA

Statistical Methods for Population Genomics and "Next-gen" Sequencing Data

$399,128
Paul A Scheet · University Of Tx Md Anderson Can Ctr · R01 · FY2011 · HG

A redox-mediated mechanism of UVB-induced metabolic switch in skin carcinogenesis

$399,091
Daret K St Clair · University Of Kentucky · R01 · FY2019 · CA

Antigen-independent prediction and biomarker identification of cancer-specific T cells

$399,032
Bo Li · Children'S Hosp Of Philadelphia · R01 · FY2023 · CA

The mutational mechanisms shaping melanocytes in human skin

$399,002
Alan Hunter Shain · University Of California, San Francisco · R01 · FY2024 · AR